These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8546131)

  • 1. Rusty peritoneal dialysis fluid after intravenous administration of iron dextran.
    Carter TB; Garris AG; Ullian ME
    Am J Kidney Dis; 1996 Jan; 27(1):147-50. PubMed ID: 8546131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of iron deficiency by a bolus intravenous iron dextran in peritoneal dialysis].
    Ficheux M; Cuny P; Lecouf A; Ryckelynck JP; Hurault de Ligny B; Lobbedez T
    Nephrol Ther; 2011 Dec; 7(7):558-61. PubMed ID: 21715234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electron microscopic study of the peritoneal kinetics of iron dextran during peritoneal dialysis in the rabbit.
    Digenis GE; Rabinovich S; Medline A; Rodella H; Wu G; Oreopoulos DG
    Nephron; 1984; 37(2):108-12. PubMed ID: 6728083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products.
    McCarthy JT; Regnier CE; Loebertmann CL; Bergstralh EJ
    Am J Nephrol; 2000; 20(6):455-62. PubMed ID: 11146312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absorption of iron dextran from the peritoneal cavity of rats.
    Suzuki K; Twardowski ZJ; Nolph KD; Khanna R; Moore HL
    Adv Perit Dial; 1995; 11():57-9. PubMed ID: 8534738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of bolus intraperitoneal iron dextran in continuous ambulatory peritoneal dialysis or continuous cyclic peritoneal dialysis patients receiving recombinant human erythropoietin.
    Mars RL; Moles K; Pope K; Hargrove P
    Adv Perit Dial; 1999; 15():60-4. PubMed ID: 10682073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of bolus intravenous iron dextran treatment in peritoneal dialysis patients receiving recombinant human erythropoietin.
    Ahsan N; Groff JA; Waybill MA
    Adv Perit Dial; 1996; 12():161-6. PubMed ID: 8865893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vancomycin pharmacokinetics in patients undergoing chronic intermittent peritoneal dialysis.
    Glew RH; Pavuk RA; Shuster A; Alfred HJ
    Int J Clin Pharmacol Ther Toxicol; 1982 Dec; 20(12):559-63. PubMed ID: 7152738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized cross-over study of adverse reactions and cost implications of intravenous push compared with infusion of iron dextran in hemodialysis patients.
    St Peter WL; Lambrecht LJ; Macres M
    Am J Kidney Dis; 1996 Oct; 28(4):523-8. PubMed ID: 8840941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peritoneal transport of vancomycin during peritoneal dialysis.
    Nielsen HE; Sørensen I; Hansen HE
    Nephron; 1979; 24(6):274-7. PubMed ID: 514426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron dextran treatment in peritoneal dialysis patients on erythropoietin.
    Suh H; Wadhwa NK
    Adv Perit Dial; 1992; 8():464-6. PubMed ID: 1361849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful administration of iron dextran in a patient who experienced a life threatening reaction to intravenous iron dextran.
    Hickman MA; Bernstein IL; Palascak JE
    Ann Allergy Asthma Immunol; 2000 Feb; 84(2):262-3. PubMed ID: 10719785
    [No Abstract]   [Full Text] [Related]  

  • 13. A protocol for administering intravenous iron dextran in peritoneal dialysis patients.
    Huff J
    ANNA J; 1998 Aug; 25(4):419-23. PubMed ID: 9791315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pigment epitheliopathy with serous detachment of the retina following intravenous iron dextran.
    Hodgkins PR; Morrell AJ; Luff AJ; Fetherston TJ; Good P
    Eye (Lond); 1992; 6 ( Pt 4)():414-5. PubMed ID: 1478317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vancomycin pharmacokinetics in patients with peritonitis on peritoneal dialysis.
    Magera BE; Arroyo JC; Rosansky SJ; Postic B
    Antimicrob Agents Chemother; 1983 May; 23(5):710-4. PubMed ID: 6870220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Pseudo-hemolytic" transfusion reaction caused by intravenous iron-dextran therapy.
    Simon SD; Kuriyan MA; Kim HC
    Transfusion; 1982; 22(4):341-2. PubMed ID: 6179270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic peritoneal dialysis in iron-deficient rats with solutions containing iron dextran.
    Reddy DK; Moore HL; Lee JH; Saran R; Nolph KD; Khanna R; Twardowski ZJ
    Kidney Int; 2001 Feb; 59(2):764-73. PubMed ID: 11168960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Splenic siderosis and parenteral iron dextran in maintenance haemodialysis patients.
    Murray JA; Slater DN; Parsons MA; Fox M; Smith S; Platts MM
    J Clin Pathol; 1984 Jan; 37(1):59-64. PubMed ID: 6707221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of an intravenous iron dextran regimen on iron stores, hemoglobin, and erythropoietin requirements in hemodialysis patients.
    Park L; Uhthoff T; Tierney M; Nadler S
    Am J Kidney Dis; 1998 May; 31(5):835-40. PubMed ID: 9590194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of intravenous iron supplementation in chronic kidney disease: an update.
    Macdougall IC; Geisser P
    Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.